These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6102775)

  • 1. RMI-81,582, a novel antipsychotic drug.
    Young MA; Meltzer HY
    Psychopharmacology (Berl); 1980 Jan; 67(1):101-6. PubMed ID: 6102775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of clozapine on human serum prolactin levels.
    Meltzer HY; Goode DJ; Schyve PM; Young M; Fang VS
    Am J Psychiatry; 1979 Dec; 136(12):1550-5. PubMed ID: 507205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years.
    Mattes JA
    J Clin Psychiatry; 1989 Oct; 50(10):389-91. PubMed ID: 2571612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
    Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
    Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risks and benefits of clozapine versus chlorpromazine.
    Claghorn J; Honigfeld G; Abuzzahab FS; Wang R; Steinbook R; Tuason V; Klerman G
    J Clin Psychopharmacol; 1987 Dec; 7(6):377-84. PubMed ID: 3323261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine--a potential antipsychotic agent without extrapyramidal manifestations.
    Matz R; Rick W; Thompson H; Gershon S
    Curr Ther Res Clin Exp; 1974 Jul; 16(7):687-95. PubMed ID: 4210458
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.
    Small JG; Milstein V; Marhenke JD; Hall DD; Kellams JJ
    J Clin Psychiatry; 1987 Jul; 48(7):263-7. PubMed ID: 2885310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluperlapine in tardive dyskinesia and parkinsonism.
    Korsgaard S; Noring U; Gerlach J
    Psychopharmacology (Berl); 1984; 84(1):76-9. PubMed ID: 6149595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters.
    Wetzel H; Szegedi A; Hain C; Wiesner J; Schlegel S; Benkert O
    Psychopharmacology (Berl); 1995 May; 119(2):231-8. PubMed ID: 7659771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
    Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
    Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison.
    Shopsin B; Klein H; Aaronsom M; Collora M
    Arch Gen Psychiatry; 1979 Jun; 36(6):657-64. PubMed ID: 375865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of a clozapine trial in neuroleptic-resistant schizophrenia.
    Meltzer HY
    Arch Gen Psychiatry; 1989 Jul; 46(7):672. PubMed ID: 2567591
    [No Abstract]   [Full Text] [Related]  

  • 14. An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels.
    Mielke DH; Gallant DM; Kessler C
    Am J Psychiatry; 1977 Dec; 134(12):1371-5. PubMed ID: 21571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluperlapine vs haloperidol: a comparison of their neuroendocrinological profiles and the influence on serum lipids.
    Fleischhacker WW; Stuppäck C; Moser C; Schubert H; Hinterhuber H
    Pharmacopsychiatry; 1986 May; 19(3):111-4. PubMed ID: 2873601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.
    Ishigooka J; Murasaki M; Miura S;
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):353-63. PubMed ID: 11442886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study.
    Gelenberg AJ; Doller JC
    J Clin Psychiatry; 1979 May; 40(5):238-40. PubMed ID: 374401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
    Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.